GUIDEWIRE
23.3.2022 07:02:05 CET | Business Wire | Press release
Guidewire (NYSE: GWRE) today announced that it has opened its new EMEA headquarters 10 years after the company opened its first office in Dublin. Based in Blanchardstown, the new office building occupies 85,000ft² and is evidence of Guidewire’s continued commitment to Ireland and its customers across Europe. Adapting to the new world of work, Guidewire is offering employees fully remote and hyperflexible working practices. As well as providing employees with a state-of-the-art work environment, the office also includes an executive briefing centre for its customer and partner community across the region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322006033/en/
Since 2011, Guidewire’s Dublin base has grown to become the company’s largest employee community in Europe and outside of the USA, including a diverse range of 35+ nationalities. Guidewire anticipates scaling headcount by about 150 new recruits to around 600 staff over the next two to three years and is actively hiring across a range of positions, from entry-level graduate roles to business analysts, cloud operations, consulting managers, engineering, HR & Recruitment, project managers, specialist cloud transition roles, and technology consultants.
Since 2016 Guidewire Dublin has made the top 20 in the Great Place to Work, including 10th place in Ireland’s Best Workplaces 2021 for best large company.
“This is an exciting moment for Guidewire in Ireland as we open our new EMEA HQ, reflecting the enormous contribution of our team to the Guidewire corporate and customer community,” said Niall Lalor, Ireland country manager, Guidewire. “As the company has grown and evolved over the past 10 years in Ireland, I’m hugely proud that we have retained our strong sense of identity and close-knit culture throughout. We’ve still only scratched the surface and look forward to growing our talented team even more across the country, with Guidewire in Dublin well placed as a hub for innovation that supports our business both in EMEA and globally.”
The Irish operations include Customer & Cloud Operations, Delivery Services, and Product Development, with teams that have spearheaded Guidewire’s digital products, created specific local solutions for European customers, as well as managed the implementations and support of the company’s first cloud customers. The siting of the cloud team in Dublin also takes advantage of access to top new graduates from Ireland, the wider European Union, and beyond.
“Ireland has been central to Guidewire’s international growth over the past 10 years,” said Mike Rosenbaum, chief executive officer, Guidewire. “It’s nothing new to say that the world has witnessed extraordinary changes over the past two years and the insurance industry is no exception. Guidewire continues to be an indispensable partner to our 450+ customers around the world. Guidewire aspires to design, build, and run a mission critical cloud service, and our team in Ireland is critical to making this a reality.”
Tánaiste and Minister for Enterprise, Trade and Employment, Leo Varadkar, TD, said “I’m so pleased Guidewire has chosen Blanchardstown for its new EMEA headquarters. Guidewire is a leading player in the software industry and this expansion, which will create an additional 150 highly skilled jobs, demonstrates the company’s continued commitment to Ireland after 10 years. I wish the team every success with their expansion plans.”
Commenting on the news Mary Buckley, Executive Director, IDA Ireland, said “Today’s announcement demonstrates Guidewire’s continued confidence in the availability of a highly skilled and talented workforce in Ireland to further support its evolution and to deliver on its strategic corporate goals. I wish the team continued success in their new office building and offer the company the ongoing support of IDA Ireland.”
Further details are available at: https://careers.guidewire.com/location/dublin
Dublin office video:
https://players.brightcove.net/929656735001/41G8Cuaute_default/index.html?videoId=6300984518001
About Guidewire
Guidewire is the platform general insurers trust to engage, innovate, and grow efficiently. We combine digital, core, analytics, and AI to deliver our platform as a cloud service. More than 450 insurers, from new ventures to the largest and most complex in the world, run on Guidewire.
As a partner to our customers, we continually evolve to enable their success. We are proud of our unparalleled implementation track record, with 1,000+ successful projects, supported by the largest R&D team and partner ecosystem in the industry. Our marketplace provides hundreds of applications that accelerate integration, localisation, and innovation.
For more information, please visit www.guidewire.com and follow us on twitter: @Guidewire_PandC .
NOTE: For information about Guidewire’s trademarks, visit https://www.guidewire.com/legal-notices
View source version on businesswire.com: https://www.businesswire.com/news/home/20220322006033/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
